135 related articles for article (PubMed ID: 15767973)
1. Two-once-daily fixed-dose NRTI combinations for HIV.
Med Lett Drugs Ther; 2005 Feb; 47(1203):19-20. PubMed ID: 15767973
[TBL] [Abstract][Full Text] [Related]
2. Switching Combivir to Truvada keeps HIV undetectable, improves blood fats, fails to improve limb fat.
Proj Inf Perspect; 2008 Dec; (47):8. PubMed ID: 19227559
[No Abstract] [Full Text] [Related]
3. Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study.
Cohen CJ; Kubota M; Brachman PS; Harley WB; Schneider S; Williams VC; Sutherland-Phillips DH; Lim ML; Balu RB; Shaefer MS;
Pharmacotherapy; 2008 Mar; 28(3):314-22. PubMed ID: 18294111
[TBL] [Abstract][Full Text] [Related]
4. A truvada hypersensitivity reaction simulating abacavir hypersensitivity.
de Perio MA; Gomez FJ; Frame PT; Fichtenbaum CJ
AIDS; 2007 Oct; 21(16):2252-3. PubMed ID: 18090057
[No Abstract] [Full Text] [Related]
5. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
Martin A; Bloch M; Amin J; Baker D; Cooper DA; Emery S; Carr A
Clin Infect Dis; 2009 Nov; 49(10):1591-601. PubMed ID: 19842973
[TBL] [Abstract][Full Text] [Related]
6. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
Bickel M; Bodtländer A; Knecht GK; Stephan C; von Hentig N; Kurowski M; Gute P; Klauke S; Lutz T
J Antimicrob Chemother; 2009 Dec; 64(6):1260-4. PubMed ID: 19776037
[TBL] [Abstract][Full Text] [Related]
7. [Two novel fixed formulations of nucleoside analogues (tenofovir-emtricitabine, and abacavir-lamivudine). Prospective, open study on clinical practice and therapeutic perspectives, in patients naïve and in subjects pre-treated with antiretrovirals].
Manfredi R; Calza L
Recenti Prog Med; 2008 Oct; 99(10):492-501. PubMed ID: 19040127
[TBL] [Abstract][Full Text] [Related]
8. Emtricitabine: new preparation. An antiretroviral very similar to lamivudine.
Prescrire Int; 2005 Apr; 14(76):54-6. PubMed ID: 15875341
[TBL] [Abstract][Full Text] [Related]
9. Emtricitabine/tenofovir (Truvada) for HIV prophylaxis.
Coutinho B; Prasad R
Am Fam Physician; 2013 Oct; 88(8):535-40. PubMed ID: 24364575
[No Abstract] [Full Text] [Related]
10. Zidovudine + lamivudine: new preparation. Fewer tablets required.
Prescrire Int; 1999 Apr; 8(40):39-40. PubMed ID: 10848057
[TBL] [Abstract][Full Text] [Related]
11. 144-week data released on Gilead's study 934.
AIDS Patient Care STDS; 2007 Aug; 21(8):603-4. PubMed ID: 17902243
[No Abstract] [Full Text] [Related]
12. Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients.
Rousseau FS; Wakeford C; Mommeja-Marin H; Sanne I; Moxham C; Harris J; Hulett L; Wang LH; Quinn JB; Barry DW;
J Infect Dis; 2003 Dec; 188(11):1652-8. PubMed ID: 14639535
[TBL] [Abstract][Full Text] [Related]
13. Truvada and Epivir are similar at suppressing HIV.
Proj Inf Perspect; 2009 Mar; (48):5-6. PubMed ID: 19492457
[No Abstract] [Full Text] [Related]
14. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.
Stellbrink HJ; Orkin C; Arribas JR; Compston J; Gerstoft J; Van Wijngaerden E; Lazzarin A; Rizzardini G; Sprenger HG; Lambert J; Sture G; Leather D; Hughes S; Zucchi P; Pearce H;
Clin Infect Dis; 2010 Oct; 51(8):963-72. PubMed ID: 20828304
[TBL] [Abstract][Full Text] [Related]
15. [Simply convincing. New fixed combination for HIV therapy].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():20-3. PubMed ID: 16385865
[No Abstract] [Full Text] [Related]
16. The art of managing human immunodeficiency virus infection: a balancing act.
Reiss P
Clin Infect Dis; 2009 Nov; 49(10):1602-4. PubMed ID: 19842978
[No Abstract] [Full Text] [Related]
17. Minor emtricitabine intolerance in treatment-stable patients switched from tenofovir/lamivudine to a fixed-dose combination of tenofovir/emtricitabine (Truvada).
Palacios R; Terrón A; Hidalgo A; Rivero A; Santos J;
J Antimicrob Chemother; 2008 Feb; 61(2):462-3. PubMed ID: 18156608
[No Abstract] [Full Text] [Related]
18. New once-a-day drugs: Truvada and Epzicom.
Berger DS
Posit Aware; 2004; 15(6):38-9. PubMed ID: 15619773
[No Abstract] [Full Text] [Related]
19. Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.
Muñoz de Benito RM; Arribas López JR
Expert Rev Anti Infect Ther; 2006 Aug; 4(4):523-35. PubMed ID: 17009933
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?
De Clercq E
Med Res Rev; 2012 Jul; 32(4):765-85. PubMed ID: 22581627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]